Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic injection 0.5 mg + basal insulin MET 10.7% with Ozempic injection 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified

In a twist of irony, on the same day, large parts of Los Angeles County were engulfed in what would turn out to be one of the most destructive fires in Californias history
Arginine enhances blood flow and insulin response, two key factors in metabolic efficiency
Liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks in adolescents with obesity, while placebo reduced BMI by 0.3% in the long term [115]
L-theanine could alleviate the memory impairment of the aging mouse by upregulating janus kinase 2 (JAK2)/activator of transcription 3 (STAT3), M1 muscarinic cholinergic receptor (mAChR), and extracellular signal-regulated kinase (ERK) signaling (49)
The mean changes in height SDS from baseline in years 2 through 5 of treatment were + 0.6 (SD = 0.6), + 0.8 (SD = 0.7), + 1.0 (SD = 0.6), and + 1.1 (SD = 0.7), respectively